Cretostimogene

Cretostimogene grenadenorepvec is an oncolytic adenovirus developed by CG Oncology (NASDAQ: CGON) for non-muscle invasive bladder cancer (NMIBC), the most common form of bladder cancer that hasn't grown into the muscle wall. In the Phase 3 BOND-003 trial, cretostimogene delivered a 75.5% complete response rate in patients whose cancer stopped responding to BCG - the decades-old standard treatment - with zero grade 3 or higher side effects [1]. CG Oncology is completing a rolling BLA submission in 2026, has $903 million in cash, a ~$5.4 billion market cap, and is building toward what could be the best-in-class intravesical therapy in a space where an ongoing global BCG shortage has left patients with few good options [2].

Cretostimogene holds both Breakthrough Therapy Designation and Fast Track Designation from the FDA, granted in December 2023 for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) [3]. CG Oncology initiated a rolling BLA submission in the second half of 2025 and expects to complete it in 2026, targeting the initial indication of high-risk BCG-unresponsive NMIBC with CIS with or without papillary (Ta/T1) tumors [2]. Assuming completion mid-2026 and priority review (which Breakthrough Therapy recipients typically receive), a PDUFA date could fall in late 2026 or early 2027. This is a novel compound - cretostimogene has never been approved anywhere. The broader development program spans over 600 patients across multiple trials. Beyond the BLA-supporting BOND-003 study, CG Oncology is running PIVOT-006 (NCT06111235), a Phase 3 randomized trial in intermediate-risk NMIBC that could significantly expand the addressable population [4]. The CORE-008 program is testing combinations in BCG-naive patients, pushing cretostimogene upstream from last-line to earlier treatment settings. CG Oncology raised $437 million in its January 2024 IPO and held $903 million in cash as of February 2026, funding operations into the first half of 2029 with minimal debt [2].

Cretostimogene is an engineered virus that kills bladder cancer cells from the inside while training the immune system to recognize and attack the tumor. Here's how it works. The virus is built on an adenovirus backbone - the same family of viruses that cause the common cold - but modified so it can only replicate inside cancer cells. The key is a protein called Rb (retinoblastoma protein), which normally acts as a brake on cell division. In healthy cells, Rb keeps a transcription factor called E2F locked down, which prevents the virus from switching on. But in bladder cancer cells, the Rb pathway is broken in over 90% of cases [5]. With Rb disabled, E2F runs unchecked, and the virus replicates aggressively inside tumor cells, bursting them open. The released viral copies then infect neighboring cancer cells, creating a chain reaction confined to malignant tissue. The second trick: as infected cancer cells rupture, they release GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune-signaling protein that the virus was engineered to produce. GM-CSF recruits dendritic cells - the immune system's scouts - to the tumor site, where they pick up tumor debris and present it to T-cells. This converts oncolysis into an in situ vaccination: the dying tumor teaches the immune system what bladder cancer looks like [6]. The result is both immediate tumor killing and longer-lasting immune memory, which likely explains the durable responses seen in trials. Because cretostimogene is delivered directly into the bladder via catheter (intravesical administration), systemic exposure is minimal - explaining why zero patients in BOND-003 experienced grade 3 or higher treatment-related adverse events [1].

The BLA-supporting study is BOND-003 Cohort C (NCT04452591), a Phase 3, single-arm, multinational trial of intravesical cretostimogene in 110 patients with high-risk BCG-unresponsive NMIBC with CIS, with or without concurrent papillary disease [1]. The single-arm design is standard for this setting - the FDA has accepted it for prior approvals of Adstiladrin and Anktiva, given the lack of effective alternatives in BCG-unresponsive patients. The primary endpoint is complete response rate. Results as of the March 2025 data cutoff (median follow-up 22.3 months): CR at any time was 75.5% (83/110, 95% CI 66.3-83.2%). The 12-month CR rate was 46.4% and estimated 24-month CR rate was 42.3%. Kaplan-Meier estimated duration of response at 24 months was 58.3%, with a median DOR of 27.9 months (ongoing). At 24 months, 97.3% of patients were free from progression to muscle-invasive disease, and 84.5% had avoided radical cystectomy - the bladder removal surgery that represents the standard alternative [1]. BOND-003 Cohort P separately evaluated cretostimogene in 51 patients with papillary-only (no CIS) BCG-unresponsive disease. High-grade event-free survival was 95.7% at 3 months, 84.6% at 6 months, and 80.4% at 9 months, with no cystectomies and no muscle-invasive progression [7]. PIVOT-006 (NCT06111235) is a Phase 3 randomized trial (n=367) testing cretostimogene as adjuvant therapy after TURBT in intermediate-risk NMIBC, with recurrence-free survival as the primary endpoint - topline data expected first half of 2026 [4].

The model gives this drug a 19% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 48% - then adjusts up or down based on ten facts about the trial and its sponsor. The biggest boost comes from the trial's light or open-label blinding; the biggest drags are the sponsor's thin approval record, weak earlier-phase results, and a randomized design. The remaining factors were close to average and left the estimate roughly where the base rate set it.

Cretostimogene is a strong signal, not noise. The data package is the best monotherapy result in BCG-unresponsive NMIBC - 75.5% CR beats Adstiladrin's 51% and Anktiva's 62%, with a cleaner safety profile than either. The only durability question mark is Anktiva's reported 45.4-month median DOR, but Anktiva requires BCG co-administration, which is a serious practical constraint during a global BCG shortage that has persisted since 2012. The competitive dynamics are favorable. Adstiladrin's median DOR of 9.7 months means many patients relapse within a year. Pembrolizumab's 41% CR rate in KEYNOTE-057 is the weakest of the group and carries systemic immune side effects. CG Oncology's strategic play - pushing cretostimogene upstream into BCG-naive (CORE-008) and intermediate-risk (PIVOT-006) populations - could transform this from a last-line rescue therapy into a backbone treatment across NMIBC risk categories [4][8]. The CORE-001 combination data with pembrolizumab (57.1% CR at 12 months, 51.4% at 24 months) adds optionality [6]. Key data points to watch: BLA completion and PDUFA date assignment (expected 2026), PIVOT-006 topline data (H1 2026), and CORE-008 Cohort CX combination results. At ~$5.4 billion market cap, the stock already prices in a high probability of approval, so the upside catalyst is more likely TAM expansion via PIVOT-006 than the BLA itself. Check back at PDUFA date announcement and PIVOT-006 readout.